Effect of Compacept on plasma metabolism regulation in the treatment of diabetic macular edema

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400093818

Enrollment

Unknown

Registered

2024-12-12

Start date

2024-01-02

Completion date

Unknown

Last updated

2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic macular edema, DME

Interventions

Response to Compaq Cept group:NA

Weak response group:NA

No response group:NA

Eligibility

Sex/Gender

All

Age

30 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.age>=30; 2.diagnosis was diabetic macular edema; 3.receive at least one intravitreal injection of Compacept;

Exclusion criteria

Exclusion criteria: 1.Intravitreal or systemic administration of Compacept within 3 months; 2.Other interventional treatments (e.g. photodynamic therapy, retinal photocoagulation, ciliary vitrectomy, etc.) within 3 months; 3.Other causes of subretinal fluid accumulation/bleeding, such as diabetic retinopathy, retinal vein obstruction, etc; 4.Serious systemic disease, such as kidney failure;

Design outcomes

Primary

Measure	Time frame
Absorption of subretinal fluid or visual acuity after treatment;Metabolism and lipidomics;	—

Countries

China

Contacts

Public ContactChun Ding

Second Xiangya Hospital of CSU

chunding@csu.edu.cn+86 186 7079 2378

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026